Langenthal

Researchers are evaluating the safety and clinical performance of the Dexter Robotic System in patients undergoing robotic-assisted right colectomy. This study focuses on confirming the perioperative and early postoperative safety as well as the effectiveness of this robotic surgical system in these patients. The study involves performing a right colectomy using the Dexter robotic surgery system, which assists the surgeon during the operation. The procedure is robotic-assisted and aims to support surgical precision and control. There is a 30-day follow-up period after surgery to monitor outcomes. Participants will undergo the robotic-assisted right colectomy and will be monitored for safety for up to 30 days after the surgery. The study will assess primary safety outcomes during this period and evaluate efficacy during the surgery itself. Patients will have follow-up assessments according to standard care procedures to track recovery and any complications.

Gastroentero-pancreatic neuroendocrine tumours GEP-NETs are rare cancers arising from the neuroendocrine cells in the gastrointestinal tract and pancreas. These tumours share common clinical features but their cell biology and mechanisms are not well understood, limiting targeted treatments. The SwissNET registry is designed to collect detailed information to better understand GEP-NETs and improve management strategies in Switzerland. This study collects data prospectively from patients diagnosed with neuroendocrine tumours confirmed by tissue analysis, regardless of the tumours original location. Data entry is anonymized and gathered from hospitals and general practitioners across Switzerland. A study nurse visits contributing centers to review patient files, and a review board addresses conflicting information. The registry monitors treatment approaches including surgery, medical therapy, and peptide-receptor radionuclide therapy. Participants provide informed consent for their data to be included. Researchers regularly evaluate patient outcomes such as tumour-related mortality and hospitalisation rates every five years. The registry also tracks the incidence of GEP-NETs in Switzerland and the effects of different treatments over time. This ongoing data collection aims to improve understanding and guide future care for patients with neuroendocrine tumours.